Avidity Biosciences, Inc.
aviditybiosciences.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2025 10-K, filed Feb 23, 2026. Its latest SEC filing is a SCHEDULE 13G/A from May 15, 2026.
10-K for FY2025, filed Feb 23, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops antibody-linked RNA drug candidates for people with Duchenne, myotonic and facioscapulohumeral muscular dystrophy.
10-K for FY2025, filed Feb 23, 2026
How Did They Make Money?
Collaborators pay upfront license fees, development, regulatory and commercial milestones, and for research, development or manufacturing services; the company may also receive royalties on licensed-product sales. Payments follow each contract’s billing schedule, and royalties arise when licensed-product sales occur.
10-K for FY2025, filed Feb 23, 2026To date, all the Company’s revenue has been derived from collaboration and research agreements. The terms of these arrangements include the…View ↗
The Company receives payments from its collaborators based on billing schedules established in each contract. Upfront and other payments…View ↗
License fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified…View ↗
$18.8M
-
10-K for FY2025, filed Feb 24, 2026
$18.8M ↗
Who Were Their Customers?
Collaborators contract with Avidity through research and collaboration agreements; the filing names Bristol Myers Squibb and Eli Lilly as partners.
10-K for FY2025, filed Feb 23, 2026
Did Revenues Turn Into Profits?
No. It lost $684.6M in FY2025.
10-K for FY2025, filed Feb 24, 2026
−$745.9MView ↗
10-K for FY2025, filed Feb 24, 2026
−$684.6MView ↗
10-K for FY2025, filed Feb 24, 2026
−$663.8MView ↗
How Were They Changing?
-
Feb 27, 2026
Merger changed control and made Avidity a wholly owned subsidiary
Nasdaq trading was set to be suspended on March 2, 2026.
Sources
8-K, filed Feb 27, 2026
On February 27, 2026, the Company (i) notified the Nasdaq Global Select Market (“Nasdaq”) of the consummation of the Merger and its intent…View ↗
Grew. Revenue grew 2.0x in 4 years, from $9.3M in FY2021 to $18.8M in FY2025, about 19% a year.
Cardiology programs separated
A planned separation moves early precision cardiology assets and related collaborations into SpinCo, while the older report described cardiac and immunology work within Avidity’s pipeline and partnerships.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 23, 2026As we grow the company, we plan to continue to employ a disciplined strategy to maximize the value of our pipeline by retaining development…View ↗
In connection with the Merger, we, Atrium Therapeutics, Inc. (formerly known as Bryce Therapeutics, Inc., a newly formed Delaware…View ↗
Who Did They Compete With?
Competes with Dyne Therapeutics, AMO Pharma, PepGen, Sarepta, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, Entrada, Sanofi, F. Hoffmann-La Roche, Epicrispr Biotechnologies, Restem, Novartis, Armatus Bio, Altay Therapeutics, Vita Therapeutics, Modalis Therapeutics, OligomicsTx, Celularity, Souffle Therapeutics, and PTC Therapeutics
10-K for FY2025, filed Feb 23, 2026There are currently no approved therapies treating the underlying cause of DM1. However, several products are in clinical development for…View ↗
Loading...
